Table 2.
Compounds | Experimental Model | Effective Dose | Targets | Target Process | Effect | References |
---|---|---|---|---|---|---|
γ-oryzanol | Male C57BL/6 mice | 14.78 mg/kg/d | PPARδ ERRγ |
Upregulate mitochondrial biogenesis and promote fatty acid β-oxidation | Reduce muscle weakness, alleviate inflammation and enhance muscle strength | [121] |
Male Wistar rats | 0.5% (w/w) | GLUT4 | Promote antioxidant and anti-inflammatory effects | Alleviate insulin resistance in muscle | [122] | |
β-sitosterol | ICR mice C2C12 cells |
35 or 350 μg/kg/d 15 μM | UCP3 | Upregulate the activity of complex proteins in the mitochondrial electron transport chain and induce mitochondrial uncoupling | Meet energy demand and promote muscle strength | [126] |
Broilers | 100 mg/kg | PGC-1α/TFAM signaling | Upregulate oxidative status and mitochondrial biogenesis | Promote muscle performance | [127] | |
L6 cells | 20 μM | LKB1/AMPK signaling | Increase ACC phosphorylation and triglyceride metabolism | Promote glucose homeostasis and lipid metabolism | [128] | |
Male diabetic rats | 20 mg/kg/d | Rab/IRAP/Munc 18 pathway | Upregulate GLUT4 translocation and glycolytic and gluconeogenesis enzymes | Alleviate insulin resistance in muscle | [129] | |
Male C57BL/6 mice | 200 mg/kg/d | FoxO1 signaling | Alleviate muscle protein loss and inhibit protein degradation | Alleviate muscle atrophy | [157] | |
Alkylresorcinols | Male C57BL/6 mice | 0.4% (w/w) | Pyruvate dehydrogenase kinase 4 (PDK4) | Promote lipid-autophagy-induced lipid metabolism disorder | Inhibit the reduction in muscle size and prevent muscle atrophy | [4] |
Male Wistar rats | 400 mg/kg/d | Glutathione peroxidase (GPx) | Inhibit oxidative damage caused by lipid accumulation and increase the expression of lactate dehydrogenase (LDH), alanine transaminase (ALT) | Alleviate myocardial infarction and exert an anti-fatigue effect | [130] | |
Male C57BL/6J mice | 30 or 150 mg/kg/d | SIRT3/PGC-1α signaling | Increase mitochondrial content and mitochondrial biogenesis | Improve exercise capacity | [131] | |
Ferulic acid | Male SD rats | 0.6 mg/kg/d | PKCε | Inhibit lipid-accumulation-induced inflammation | Alleviate insulin resistance | [44] |
Isolated rat psoas muscle cells from Sprague Dawley male albino rats | 15–240 µg/mL | α-glucosidase and α-amylase | Promote fatty acid oxidative decomposition and inhibit carbohydrate and lipid hydrolyzing enzymes | Alleviate oxidative stress and mitigate redox imbalance | [5] | |
C2C12 cells | 25 μM | PI3K/Cpkc signaling | Promote glucose uptake and glycogen synthesis | Improve insulin resistance | [45] | |
Zebrafish | 0.06 mg/d | MyoD myogenin |
Promote muscle growth | Increase the CSA of muscle fiber and muscle mass | [46] | |
Duroc × Landrace × Yorkshire (DLY) weaned piglets | 0.05% or 0.45% (w/w) | SIRT1/AMPK/PGC-1α signaling | Improve the activity of SDH and MDH, increase the expression of slow MyHC protein |
Increase the proportion of slow-twitch fiber and promote mitochondria function | [47] | |
C2C12 cells | 0.5 or 1 μM | SIRT1/AMPK signaling | Increase the protein level of slow MyHC and decrease the protein level of fast MyHC | Promote slow oxidative muscle fiber formation and inhibit fast muscle fiber formation and exert an anti-fatigue function | [48] | |
p-coumaric acid | L6 cells | 100 μM | AMPK signaling | Promote the fatty acid β-oxidation | Inhibit lipid-accumulation-induced inflammation in muscle | [53] |
C2C12 cells | 0.1 mM | AMPK signaling | Increase expression of myogenin and myoD | Improve myogenic differentiation | [52] | |
Resveratrol | Male C57 BL/6J mice | 50 mg/kg/d | AMPK/ FOXO3 signaling |
Improve mitochondrial function | Improve muscle atrophy | [55] |
Male C57BL/6J mice | 0.4% (w/w) | AMPK/PGC-1α signaling | Increase the level of muscle regeneration proteins including MyoG, Myf5 and Pax7 and mitochondrial biogenesis | Enhance muscle proliferation, differentiation and regeneration of impaired muscle | [57] | |
L6 cells | 25 μM | PKA/LKB1/ AMPK pathway |
Improve mitochondrial dysfunction and oxidative stress | Increase muscle mass and myofiber size and improve induced muscle atrophy | [56] | |
Male C57BL/6J mice | 15 mg/kg/d | Increase muscle glycogen synthesis and reduce ROS levels | Reduce insulin resistance and promote lipid metabolism | [58] | ||
C2C12 cells | 50 μM | AKT signaling | Modulate redox levels and glucose absorption | Reduce insulin resistance | [59] | |
C2C12 cells | 100 μM | AKT/mTOR/FOXO1 signaling | Inhibit the atrophy-related ubiquitin ligase | Improve muscle hypertrophy and muscle atrophy | [60] | |
Male Kunming mice | 400 mg/kg/d | AdiopR1–AMPK–PGC-1α signaling | Increase the expression of myosin heavy chain (MyHC) 1, MyHC2a and MyHC2x | Improve the transformation from fast- to slow-twitch muscle fibers and exercise performance | [61] | |
C2C12 cells | 50 μM | miR-22-3p | Increase the activities of lactate dehydrogenase (SDH) and malate dehydrogenase (MDH) | Promote muscle-fiber-type conversion from fast-twitch to slow-twitch muscle fibers and exert an anti-fatigue effect | [62] | |
Male ICR mice | 25 mg/kg/d | Increase the activities of LDH (lactic dehydrogenase) and creatine kinase (CK) | Improve muscle recovery and inflammation | [63] | ||
Quercetin | Male Balb/c mice | 0.5% (w/w) | Adiponectin signaling | Decrease the fast MyHC and MyHC IIb protein expression |
Promote muscle-fiber-type transformation from fast-twitch to slow-twitch muscle fibers | [66] |
Male C57BL/6 mice | 0.05% (w/w) | HO-1/NRF2 signaling | Decrease inflammatory response and oxidative stress | Reduce obesity-induced muscle atrophy | [68] | |
Male C57BL/6 mice | 0.2% (w/w) | PGC-1α signaling | Improve mitochondrial biogenesis and oxidative phosphorylation | Alleviate disuse-induced muscle atrophy | [69] | |
C2C12 cells | 20 µM | AMPK signaling | Enhance insulin-stimulated glucose uptake and decrease inflammatory response | Ameliorate inflammation-induced insulin resistance | [70] | |
Oligomeric procyanidins (OPCs) | Male ICR mice | 15 mg/kg/d | mTOR signaling | Increase glucose uptake and glycolysis, improve heat generation and inhibit gluconeogenesis and lipogenesis | Improve glucose homeostasis, lipid metabolism and insulin sensitivity | [75] |
Human primary skeletal muscle cells | 10 or 25 μM | AKT signaling | Increase glycogen synthesis and glucose uptake | Improve glucose utilization and alleviate insulin resistance | [76] | |
Male ICR mice | 10 μg/kg/d | AMPK signaling | Promote GLUT4 translocation | Increase insulin sensitivity | [77] | |
Cyanidin-3-glucoside (Cy3G) | Male ICR mice | 1 mg/kg/d | PGC-1α signaling | Improve mitochondrial content and mitochondrial biogenesis | Improve exercise capacity | [82] |
Human skeletal muscle cells | 100 µM | Inhibit the activity of α-amylase and α-glucosidase | Alleviate diabetes | [81] | ||
Catechin | C2C12 cells | 20 µM | MyoD, MyoG, and MyHC | Promote myotube differentiation | Improve skeletal muscle regeneration and repair | [87] |
Male C57BL/6 mice | 25 mg/kg/d | Wnt signaling | Promote myotube differentiation | Promote muscle regeneration | [90] | |
C2C12 cells | 10 μM | Akt | Promote myotube differentiation | Improve muscle regeneration | [86] | |
Male rats | 1.0 mg/kg/d | p38 MAPK signaling | Promote mitochondrial respiratory capacity and mitochondrial biogenesis | Enhance the ability of resisting fatigue | [88] | |
Male Goto–Kakizaki (GK) rats | 100 mg/kg/d | ROS-ERK/JNK-p53 pathway | Promote mitochondrial autophagy | Alleviate diabetic-induced sarcopenia | [89] | |
Male Sprague Dawley rats | 200 mg/kg/d | IGF-1 | Downregulate UPS-mediated muscle protein degradation and upregulate IGF-1-mediated muscle protein synthesis | Increase muscle mass | [91] | |
Male SD rats | 0.1% (w/w) | Inhibit the expression of oxidative-modified proteins | Prevent muscle from oxidative stress induced by free radicals | [92] | ||
Rutin | Male Sprague Dawley rats | 0.1% (w/w) | AMPK signaling | Enhance mitochondrial DNA (mtDNA) content and mitochondrial biogenesis | Improve obesity-induced muscle mitochondrial dysfunction | [97] |
Male C57BL/6 mice | 60 mg/kg/d | PGC-1α signaling | Upregulate mediated mitochondrial biogenesis and decrease the level of lactic acid | Improve fatigue-resistance capacity | [98] | |
C2C12 cells | 100 μM | NF-κB signaling | Decrease the expression of IL-6 and iNOS and the production of ROS | Inhibit oxidative-stress-induced skeletal muscle injury | [99] | |
Lutein | Male Wistar rats | 0.5 mg/kg/d | NF-κB signaling | Reduce oxidative stress and inflammation and decrease the production of ROS | Improve skeletal muscle IR injury | [103] |
β-carotene | Male Kwl: ddY mice | 0.5 mg/kg/d | IGF-1 | Promote protein synthesis and reduce ubiquitin-mediated muscle protein degradation | Increase muscle mass and prevent muscle hypertrophy | [105] |
C2C12 cells | 10 μM | FOXO3A | Decrease the level of Atrogin-1 and MuRF1 | Increase muscle mass and exhibit an improvement effect on oxidative-stress-induced muscle atrophy | [107] | |
Betaine | C2C12 cells | 10 mM | NFATc1/ MyoD signaling |
Upregulate the expression of miR-29b-3p and promote myotube differentiation and the expression of slow MyHC proteins | Promote muscle cell differentiation and the transformation from fast muscle to slow muscle fiber | [136] |
C2C12 cells | 10 mM | IGF-1 signaling | Increase the expression of MyoD and myogenin | Promote muscle fiber differentiation and growth | [134] | |
C2C12 cells | 2 or 5 mM | PGC-1α signaling | Increase mitochondrial biogenesis and ATP production | Promote muscle differentiation and the transformation from fast muscle to slow muscle fiber | [137] | |
Octacosanol | Male Wistar rats | 2.0 μCi/dose | Promote energy mobilization and energy supply | Enhance physical performance | [140] | |
Male C57BL/6 mice | 200 mg/kg/d | Bcl3/TLRs/MAPK signaling | Increase the expression of Prx, Trim63 and ATPase activity | Exert an anti-fatigue effect | [143] | |
Male SD rats | 0.75% (w/w) | Creatine phosphorylation | Promote the shift from fast-twitch to slow-twitch myofibers | Exert an anti-fatigue effect | [141] | |
Male Wistar rats | 2.0 μCi/dose | ACC phosphorylation | Meet energy demand | Improve exercise capacity | [142] | |
β-glucan | Male SD rats | 312.5 mg/kg/d | Decrease the activity of lactate dehydrogenase and the creatine kinase | Increase exercise capacity and facilitate the recovery from fatigue | [116] | |
C2C12 cells | 20 mg/mL | Myf5 and Mox2 | Increase muscle cell proliferation and differentiation | Promote the transformation from fast muscle fibers to slow muscle fibers | [117] | |
Duchenne muscular dystrophy (DMD) zebrafish model | 8 mg/L | Mitochondrial respiration enzyme | Improve mitochondrial respiration and prevent oxidative stress | Improve exercise capacity | [118] | |
Tocotrienol | Male C57BL/6J mice | 100 or 300 mg/kg/d | AMPK/SIRT1/PGC-1α signaling | Upregulate the expression of proliferation and differentiation related proteins Increase mitochondrial biogenesis |
Prevent diabetes-related skeletal muscle atrophy | [110] |
Human skeletal muscle myoblasts | 50 μg/mL | miR-206 | Increase the expression of IGF1R and decrease the expression of Pax7 | Promote muscle cell proliferation and differentiation | [111] | |
Stress-induced premature senescence (SIPS) Human skeletal muscle myoblasts (CHQ5B) | 50 μg/mL | Wnt signaling FOXO pathway | Downregulate the expression of MSTN and increase the expression of muscle cells regeneration related proteins such as EREG, SHC1 and SHC3 | Promote muscle cell regeneration and alleviate muscle loss | [112] | |
Male C57BL/6J mice | 400 mg/kg/d | COXⅠ-Ⅴ | Promote mitochondrial respiration and reduce lipid peroxidation | Increase muscle mass and improve glucose homeostasis | [113] |